Pfizer And GSK Call For Early Risk Tests; Sign Of Further Vioxx Fallout?
GlaxoSmithKline will launch a risk assessment program that will allow company researchers to more rapidly recognize safety signals
You may also be interested in...
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor
Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.
The unpredictability of liver injuries associated with use of Trovan (trovafloxacin) is the challenge facing Pfizer and the probable point-of-departure for discussions with FDA.